Hims & Hers Health Faces Class Action Lawsuit Over Data Privacy Claims
Hims & Hers Health is facing a class action lawsuit alleging mishandling of consumer health data and deceptive billing practices. Investors have until November 2026 to seek appointment as lead plaintiff.
San Diego – Hims & Hers Health, Inc. (NYSE: HIMS) is subject to a class action lawsuit concerning allegations of improper handling of consumer health data and misleading billing practices. Investors who purchased or acquired the company's securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff in the action.
The lawsuit, captioned Velanki v. Hims & Hers Health, Inc., charges Hims & Hers and certain of its executives with violations of the Securities Exchange Act of 1934. The complaint alleges that the company shared sensitive consumer health information with third-party advertising platforms, including Meta and Snap, despite representations of maintaining user privacy. Furthermore, it is alleged that the company bills consumers for prescriptions almost immediately after they submit an intake form, contrary to assurances that users can consult with a medical provider to find the right treatment.
These alleged practices have reportedly exposed Hims & Hers to regulatory scrutiny and potential fines. The situation was highlighted when the Federal Trade Commission (FTC) filed a lawsuit in July 2026 against the company for these alleged transgressions. Following this announcement, Hims & Hers' stock price reportedly declined by approximately 15%.
Robbins Geller Rudman & Dowd LLP, representing the plaintiffs, is a law firm specializing in securities fraud litigation. The lead plaintiff role involves directing the litigation on behalf of the class and selecting legal counsel. An investor's ability to share in any potential recovery does not depend on serving as lead plaintiff.